Aiosyn Mitosis Breast

About Aiosyn

Aiosyn is a 2020 spin-off from Radboud University Medical Center (Radboudumc) that leverages over 20 years of research experience to build AI-powered pathology software. The company targets the clinical diagnostics and life sciences sectors with certified, workflow-integrated solutions, such as its IVDR-certified mitosis detection tool for breast cancer grading. Its strategy is rooted in close collaboration with pathologists and biopharma partners to co-develop and deploy practical AI tools that improve patient outcomes. Aiosyn is establishing itself through key partnerships and product certifications in the growing digital pathology market.

Therapeutic Areas